The University of British Columbia
UBC - A Place of Mind
The University of British Columbia Vancouver campus
Life Sciences Institute
  • HOME
  • OUR SCIENCE
    • Research Groups
    • LSI: Home to 16 Canada Research Chairs
  • OUR IMPACT
  • COMMERCIALIZATION
    • Spinoffs and Technology
    • Industrial Collaboration
    • Resources for Entrepreneurs
  • SUPPORT THE LSI
  • Faculty & Staff
    • Principal Investigators
    • Admin & Contact
    • Careers Opportunities
  • Students & Postdoctoral Fellows
    • Graduate Students & Postdoctoral Fellows
    • Undergraduate Opportunities
    • Graduate Student Association
    • Career Opportunities
  • News & Events
    • News
    • Events
  • Resources
    • Scientific Facilities & Core Services
    • Shared Equipment
    • Life Sciences Centre
    • Sustainability
    • Omics & Phenotyping Portal
    • Room Booking
    • Wing Managers
    • Toolkit
    • Used Equipment
    • Grant Facilitation
    • Electronic Lab Notebooks
  • LSI Gallery
    • 2016-17 Exhibition
    • Submissions
  • Health & Wellbeing
    • COVID-19 Info
    • Mental Health Resources
  • REDI
    • Respect, Equity, Diversity, Inclusion
  • LOGIN
Dr. Pieter Cullis

Dr. Pieter Cullis featured in Nature story on pivotal contributions to mRNA vaccines for COVID-19

September 15, 2021

“The tangled history of mRNA vaccines,” a news feature published today in Nature, reflects on the culmination of work by hundreds of scientists who worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough.

Former LSI Director Pieter Cullis is featured for his linchpin contributions in lipid nanoparticles (LNPs). “Many experts highlight another innovation that was crucial for mRNA vaccines — one that has nothing to do with the mRNA,” writes science journalist Elie Dolgin. “It is the tiny fat bubbles known as lipid nanoparticles, or LNPs, that protect the mRNA and shuttle it into cells.

“This technology comes from the laboratory of Pieter Cullis, a biochemist at the University of British Columbia in Vancouver, Canada, and several companies that he founded or led. Beginning in the late 1990s, they pioneered LNPs for delivering strands of nucleic acids that silence gene activity. One such treatment, patisiran, is now approved for a rare inherited disease.”

Read the full story via Nature online

Listen to Dr. Cullis discuss his LNP discoveries and vaccines of the future in an interview with CBC’s Quirks and Quarks

Life Sciences Institute
Vancouver Campus
2350 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 827 4128
Fax 604 827 3922
Website www.lsi.ubc.ca
Email lsi.reception@ubc.ca
Find us on
    
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility